Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.62 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 12/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7134135 | 1.00 | DRD2 (0.62) | DRD2GRM2DRD3SIGMAR1NR1H2 | |
| SCHEMBL7136208 | 0.85 | DRD2 (0.45) | DRD2DRD3NR1H2NR1H3OPRM1 | |
| SCHEMBL7136213 | 0.85 | DRD2 (0.45) | DRD2DRD3NR1H2NR1H3OPRM1 | |
| SCHEMBL3453749 | 0.77 | DRD2 (1.00) | DRD2DRD3SIGMAR1 | |
| SCHEMBL7136189 | 0.76 | DRD3 (0.47) | DRD2DRD3OPRM1 | |
| SCHEMBL7136192 | 0.76 | DRD3 (0.47) | DRD2DRD3OPRM1 | |
| SCHEMBL7136602 | 0.75 | DRD2 (0.61) | DRD2GRM2DRD3OPRM1 | |
| SCHEMBL7132786 | 0.75 | ALDH1A1 (0.55) | DRD2SIGMAR1OPRM1 | |
| SCHEMBL7136600 | 0.75 | DRD2 (0.61) | DRD2GRM2DRD3OPRM1 | |
| SCHEMBL7132782 | 0.75 | ALDH1A1 (0.55) | DRD2SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240141-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030109532-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109532-A1 | Modulators of dopamine neurotransmission | OPRD1, CHRNA5, OPRM1 | DRD2 12/4885GRM2 111/4885DRD3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.